200 related articles for article (PubMed ID: 18081894)
1. Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas.
D'Haene N; Catteau X; Maris C; Martin B; Salmon I; Decaestecker C
Br J Haematol; 2008 Feb; 140(4):402-10. PubMed ID: 18081894
[TBL] [Abstract][Full Text] [Related]
2. Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas.
Ponzoni M; Berger F; Chassagne-Clement C; Tinguely M; Jouvet A; Ferreri AJ; Dell'Oro S; Terreni MR; Doglioni C; Weis J; Cerati M; Milani M; Iuzzolino P; Motta T; Carbone A; Pedrinis E; Sanchez J; Blay JY; Reni M; Conconi A; Bertoni F; Zucca E; Cavalli F; Borisch B;
Br J Haematol; 2007 Aug; 138(3):316-23. PubMed ID: 17555470
[TBL] [Abstract][Full Text] [Related]
3. SHP-1 expression in primary central nervous system B-cell lymphomas in immunocompetent patients reflects maturation stage of normal B cell counterparts.
Sugita Y; Tokunaga O; Nakashima A; Shigemori M
Pathol Int; 2004 Sep; 54(9):659-66. PubMed ID: 15363033
[TBL] [Abstract][Full Text] [Related]
4. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers.
Legendre H; Decaestecker C; Nagy N; Hendlisz A; Schüring MP; Salmon I; Gabius HJ; Pector JC; Kiss R
Mod Pathol; 2003 May; 16(5):491-504. PubMed ID: 12748256
[TBL] [Abstract][Full Text] [Related]
5. Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance.
Raoux D; Duband S; Forest F; Trombert B; Chambonnière ML; Dumollard JM; Khaddage A; Gentil-Perret A; Péoc'h M
Neuropathology; 2010 Jun; 30(3):232-40. PubMed ID: 19925562
[TBL] [Abstract][Full Text] [Related]
6. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in primary central nervous system lymphomas.
Ferreri AJ; Reni M
Hematol Oncol Clin North Am; 2005 Aug; 19(4):629-49, vi. PubMed ID: 16083827
[TBL] [Abstract][Full Text] [Related]
8. Identification of matrix metalloproteinase-9 as an independent prognostic marker in laryngeal and hypopharyngeal cancer with opposite correlations to adhesion/growth-regulatory galectins-1 and -7.
Saussez S; Cludts S; Capouillez A; Mortuaire G; Smetana K; Kaltner H; André S; Leroy X; Gabius HJ; Decaestecker C
Int J Oncol; 2009 Feb; 34(2):433-9. PubMed ID: 19148478
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of c-Myc in primary central nervous system lymphoma of Thais.
Assanasen T; Shuangshoti S; Nilyai S; Wannakrairot P; Ruangvejvorachai P; Sawatdee R; Sangprakarn S
J Med Assoc Thai; 2006 Sep; 89 Suppl 3():S40-6. PubMed ID: 17718267
[TBL] [Abstract][Full Text] [Related]
10. Bcl-6 predicts improved prognosis in primary central nervous system lymphoma.
Levy O; Deangelis LM; Filippa DA; Panageas KS; Abrey LE
Cancer; 2008 Jan; 112(1):151-6. PubMed ID: 17999414
[TBL] [Abstract][Full Text] [Related]
11. Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer.
Saussez S; Cucu DR; Decaestecker C; Chevalier D; Kaltner H; André S; Wacreniez A; Toubeau G; Camby I; Gabius HJ; Kiss R
Ann Surg Oncol; 2006 Jul; 13(7):999-1009. PubMed ID: 16788763
[TBL] [Abstract][Full Text] [Related]
12. Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma.
Courts C; Brunn A; Montesinos-Rongen M; Siemer D; Hans V; Paulus W; Wiestler OD; Küppers R; Siebert R; Deckert M
J Neuropathol Exp Neurol; 2009 Sep; 68(9):972-6. PubMed ID: 19680146
[TBL] [Abstract][Full Text] [Related]
13. Treatment options for central nervous system lymphomas in immunocompetent patients.
Jahnke K; Thiel E
Expert Rev Neurother; 2009 Oct; 9(10):1497-509. PubMed ID: 19831839
[TBL] [Abstract][Full Text] [Related]
14. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting.
Nagy N; Legendre H; Engels O; André S; Kaltner H; Wasano K; Zick Y; Pector JC; Decaestecker C; Gabius HJ; Salmon I; Kiss R
Cancer; 2003 Apr; 97(8):1849-58. PubMed ID: 12673710
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 and Ki-67 expression in multiglandular parathyroid lesions.
Saggiorato E; Bergero N; Volante M; Bacillo E; Rosas R; Gasparri G; Orlandi F; Papotti M
Am J Clin Pathol; 2006 Jul; 126(1):59-66. PubMed ID: 16753595
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implication of p27 expression in primary central nervous system lymphoma.
Kunishio K; Nagao S
Brain Tumor Pathol; 2006 Oct; 23(2):77-81. PubMed ID: 18095123
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis, vascularity, and proliferation in primary central nervous system lymphomas (PCNSL): a histopathological study.
Roser F; Saini M; Meliss R; Ostertag H; Samii M; Bellinzona M
Surg Neurol; 2004 Nov; 62(5):393-9; discussion 399. PubMed ID: 15518841
[TBL] [Abstract][Full Text] [Related]
18. [Investigation of diagnosis and treatment for primary central nervous system lymphoma].
Meng FG; Zhang K; Mao GS; Wang ZC; Wu CY; Liu K
Zhonghua Wai Ke Za Zhi; 2007 Nov; 45(22):1549-52. PubMed ID: 18282393
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for primary central nervous system lymphoma: a case-control study.
Schiff D; Suman VJ; Yang P; Rocca WA; O'Neill BP
Cancer; 1998 Mar; 82(5):975-82. PubMed ID: 9486590
[TBL] [Abstract][Full Text] [Related]
20. Primary central nervous system lymphomas: a 30-year experience at a single institution.
Nuckols JD; Liu K; Burchette JL; McLendon RE; Traweek ST
Mod Pathol; 1999 Dec; 12(12):1167-73. PubMed ID: 10619271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]